These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 13129974)

  • 1. Glycoprotein IIb/IIIa inhibition in percutaneous coronary interventions.
    Sharma S; Nyitray W; Bhambi B
    JAMA; 2003 Sep; 290(11):1451; author reply 1451. PubMed ID: 13129974
    [No Abstract]   [Full Text] [Related]  

  • 2. [Glycoprotein IIb/IIIa antagonists].
    Hennemann A
    Med Monatsschr Pharm; 2000 Dec; 23(12):385-90. PubMed ID: 11147193
    [No Abstract]   [Full Text] [Related]  

  • 3. Should bivalirudin replace heparin during percutaneous coronary interventions?
    Antman EM
    JAMA; 2003 Feb; 289(7):903-5. PubMed ID: 12588276
    [No Abstract]   [Full Text] [Related]  

  • 4. Low-dose fibrinolytics and glycoprotein IIb/IIIa receptor blockade for the treatment of acute myocardial infarction.
    Ferrario M; Repetto A; Lucreziotti S; Ardissino D
    Am Heart J; 1999 Aug; 138(2 Pt 2):S121-5. PubMed ID: 10426870
    [No Abstract]   [Full Text] [Related]  

  • 5. Antithrombotic therapy in patients undergoing percutaneous coronary intervention.
    Popma JJ; Ohman EM; Weitz J; Lincoff AM; Harrington RA; Berger P
    Chest; 2001 Jan; 119(1 Suppl):321S-336S. PubMed ID: 11157657
    [No Abstract]   [Full Text] [Related]  

  • 6. Direct thrombin inhibitors for percutaneous coronary intervention in the current era of platelet glycoprotein IIb/IIIa inhibition.
    Reginelli JP; Chew D
    J Interv Cardiol; 2002 Apr; 15(2):141-6. PubMed ID: 12063809
    [No Abstract]   [Full Text] [Related]  

  • 7. Glycoprotein IIb/IIIa inhibition.
    Horton H
    JAMA; 2004 Nov; 292(18):2211; author reply 2211-2. PubMed ID: 15536102
    [No Abstract]   [Full Text] [Related]  

  • 8. [Antithrombotic treatment in acute coronary syndrome].
    Darius H; Rupprecht HJ; Genth-Zotz S; Wittlinger T; Zotz R
    Dtsch Med Wochenschr; 2014 Jan; 139 Suppl 1():S17-22. PubMed ID: 24446037
    [No Abstract]   [Full Text] [Related]  

  • 9. [Guidelines for percutaneous coronary interventions].
    Silber S; Albertsson P; Avilés FF; Camici PG; Colombo A; Hamm C; Jørgensen E; Marco J; Nordrehaug JE; Ruzyllo W; Urban P; Stone GW; Wijns W;
    Ital Heart J Suppl; 2005 Jul; 6(7):427-74. PubMed ID: 16082826
    [No Abstract]   [Full Text] [Related]  

  • 10. Role of tirofiban in the medical treatment of the intermediate-risk patient with an acute coronary syndrome cannot be denied.
    Goldberg L; Mekel J
    Am J Cardiol; 2000 Dec; 86(12):1401-2. PubMed ID: 11192745
    [No Abstract]   [Full Text] [Related]  

  • 11. Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial.
    Stone GW; Bertrand ME; Moses JW; Ohman EM; Lincoff AM; Ware JH; Pocock SJ; McLaurin BT; Cox DA; Jafar MZ; Chandna H; Hartmann F; Leisch F; Strasser RH; Desaga M; Stuckey TD; Zelman RB; Lieber IH; Cohen DJ; Mehran R; White HD;
    JAMA; 2007 Feb; 297(6):591-602. PubMed ID: 17299194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Standard pharmacological therapy associated with percutaneous coronary interventions in patients with stable angina].
    Karcz M; Ruzyłło W
    Kardiol Pol; 2004 Nov; 61(11):480-2. PubMed ID: 15883598
    [No Abstract]   [Full Text] [Related]  

  • 13. Use of low-molecular-weight heparin and glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
    Fernandez JS; Sadaniantz A
    Med Health R I; 2001 Feb; 84(2):37-43. PubMed ID: 11272658
    [No Abstract]   [Full Text] [Related]  

  • 14. GP IIb/IIIa blockade during peripheral artery interventions.
    Tepe G; Wiskirchen J; Pereira P; Claussen CD; Miller S; Duda SH
    Cardiovasc Intervent Radiol; 2008; 31(1):8-13. PubMed ID: 17479207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platelet glycoprotein IIb/IIIa receptor blockade: lessening the risk of coronary interventions.
    Pitts WR; Lange RA
    Thromb Haemost; 1999 Sep; 82 Suppl 1():136-8. PubMed ID: 10695505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Facilitated percutaneous coronary intervention: a novel concept in expediting and improving acute myocardial infarction care.
    Li RH; Herrmann HC
    Am Heart J; 2000 Dec; 140(6 Suppl):S125-35. PubMed ID: 11100006
    [No Abstract]   [Full Text] [Related]  

  • 17. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes.
    Campbell P
    N Engl J Med; 2001 Nov; 345(21):1573-4; author reply 1574-5. PubMed ID: 11794228
    [No Abstract]   [Full Text] [Related]  

  • 18. Impaired myocardial perfusion score and inflammatory markers in patients undergoing primary angioplasty for acute myocardial infarction.
    Exaire JE; Fathi RB; Brener SJ; Karha J; Ellis SG; Bhatt DL
    Arch Cardiol Mex; 2006; 76(4):376-82. PubMed ID: 17315613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Updated guidelines for percutaneous coronary intervention: what are the most important changes?
    Spencer BK; Smith SC
    Pol Arch Med Wewn; 2008 Mar; 118(3):96-7. PubMed ID: 18476453
    [No Abstract]   [Full Text] [Related]  

  • 20. Platelet glycoprotein IIb/IIIa inhibition during percutaneous coronary revascularization: what more needs to be proven?
    Lincoff AM; Topol EJ
    Eur Heart J; 2000 Jun; 21(11):863-7. PubMed ID: 10806004
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.